Skip to main content
. 2016 Nov 25;7(2):119–136. doi: 10.1016/j.apsb.2016.06.003

Table 1.

Activity, selectivity and bioavailability of SGLT2 inhibitors.

No. Name SGLT2 IC50 (nmol/L) SGLT1 IC50 (nmol/L) Selectivity (fold) Bioavailability (%) Condition
55 Canagliflozin 2.2 910 414 78 Launched in 2013
56 Dapagliflozin 1.1 1390 1263 78 Launched in 2014
57 Empagliflozin 3.1 > 930 >300 >90 Launched in 2014
58 Ipragliflozin 7.4 1880 254 71.7 Launched in 2014
59 Tofogliflozin 2.9 8444 2912 85 Phase III